ArticleBiomaterials advances2025
Lyophilised reservoirs in combination with hydrogel-forming microarray patches for transdermal delivery of isoniazid and pyridoxine hydrochloride.
Article in Biomaterials advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lyophilized drug reservoir-integrated hydrogel-forming microarray patches for transdermal delivery of isoniazid and pyridoxine hydrochloride as a strategy to treat latent tuberculosis.Annals of translational medicine · 2025Article
- Safety Evaluation of Repeated Application of Polymeric Microarray Patches in Miniature Pigs.Advanced healthcare materials · 2025Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis remains a major global health concern, presenting as either active disease or latent infection, the latter carrying a risk of activation, particularly in immunocompromised individuals. Prolonged isoniazid monotherapy is the standard preventive treatment, often supplemented with pyridoxine to mitigate isoniazid-induced pyridoxine depletion, as recommended by the US Centers for Disease Control and Prevention. This present study investigates an alternative transdermal approach using hydrogel-forming microarray patches (MAPs) incorporating lyophilised isoniazid and pyridoxine wafers. The MAPs were formulated with a novel poly(vinylpyrrolidone) and poly(vinyl alcohol) hydrogel, supplemented with sorbitol and adipic acid. In vitro studies demonstrated that approximately 15 % of isoniazid (8 mg) and 10 % of pyridoxine HCl (5 mg) permeated neonatal porcine skin over 24 h. In Sprague Dawley rats, MAPs provided significantly greater systemic exposure to isoniazid compared to oral administration (11,485 ± 1297 ng·mL
Indexed as
Identifiers
40382893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.